Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | HTR1A | P08908 | 3/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.67 |
| ▸ | DRD3 | P35462 | 3/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL20819249 | 0.93 | HIF1A (0.63) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| Nylidrin SCHEMBL3701975 | 0.80 | HIF1A (1.00) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| Nylidrin SCHEMBL159150 | 0.80 | HIF1A (1.00) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| Nylidrin SCHEMBL15517085 | 0.80 | HIF1A (1.00) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| SCHEMBL19329743 | 0.80 | LMNA (0.67) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| Nylidrin SCHEMBL364078 | 0.79 | ADRA1A (1.00) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| SCHEMBL16144662 | 0.78 | HIF1A (0.55) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| SCHEMBL20819250 | 0.78 | HIF1A (0.44) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| Nylidrin SCHEMBL15512520 | 0.78 | HIF1A (0.95) | HIF1AADRA1ASLC6A2OPRM1LMNA | |
| SCHEMBL19645455 | 0.77 | ESR1 (0.50) | HIF1AADRA1ASLC6A2OPRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | claimed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | claimed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | claimed |
| EP-4676481-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665321-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | Atrogi AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024184408-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024170727-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | ATROGI AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | HIF1A 527/4885ADRA1A 685/4885SLC6A2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.